Market Overview

It's A Bad Day For Biotechs

It's A Bad Day For Biotechs
Related IBB
Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading
Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares
Related XBI
Analysis: White House Takes Bully Pulpit Approach On Drug Pricing Reform, Congress Unlikely To Act
'Right To Try' Law Signed By Trump Increases Patient Access To Experimental Drugs
Buffett, Dimon and Bezos name CEO for healthcare venture (Seeking Alpha)

Biotech stocks are off to a rough start on Thursday, especially Celgene Corporation (NASDAQ: CELG), as shares plummeted to a new 52-week low of $95.50.

Celgene reported Wednesday mixed third-quarter results, but investors appear to be fixated on the company's 2020 guidance update. The company revised its 2020 earnings per share guidance from more than $13.00 to more than $12.50 per share. Revenue for 2020 was also lowered from more than $21 billion to a new range of $19 billion to $20 billion.

Celgene's revised longer-term outlook appears to be impacting the entire sector as evidence by a 2-percent decline in the biotechnology" exchange traded fund, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB). Another commonly used ETF to track the biotech sector, the SPDR S&P Biotech (ETF) (NYSE: XBI), was lower by over 1.5 percent.

The negative overhang from Celgene's earnings report appears to be taking precedent over favorable news. For example, Amgen, Inc. (NASDAQ: AMGN) reported a better than expected third-quarter report and even raised its full-year fiscal 2017 outlook, but the stock was trading lower by over 1.6 percent after Thursday's opening bell.

Here is a summary of how other notable names in the biopharmaceutical space.

  • AbbVie Inc (NYSE: ABBV): Down 4.11 percent at $88.00.
  • Gilead Sciences, Inc. (NASDAQ: GILD): Down 1.74 percent at $78.50.
  • Biogen Inc (NASDAQ: BIIB): Down 1.75 percent at $309.11.
  • Sarepta Therapeutics Inc (NASDAQ: SRPT): Up 0.92 percent at $48.81.

Related Links:

BMO: Biogen's Risks Quickly Becoming Priced In, But This May Not Be The Bottom

Tuesday's Biggest Stock Mover: Pain Therapeutics A Pleasure For Investors

Posted-In: Biotech biotechnologyBiotech Earnings News Movers General Best of Benzinga


Related Articles (AMGN + ABBV)

View Comments and Join the Discussion!